re: AXYX,
09:36 ET AXYX called #1 near-term idea at Sandler; target $15 4.97 +0.07: Sandler & Co names Axonyx as their #1 idea going into next week's JP Morgan Healthcare conference (co presents on Jan 13), with a $15 target; firm is hearing that not only is the co's Phenserine (for Alzheimers) acting with the highest AChE specificity, but also acts as an APP inhibitor, and they believe that the drug may demonstrate an ability to stop or even reverse the process of Alzheimers, with a superior side effect profile. Also, firm would not be surprised if a major pharmaceutical commercial deal for Phenserine occurs in 1H04.
